13 completed, 1 unknown. 5 Phase 1, 5 Phase 2, 5 Phase 3, 1 Not applicable.
By phase and status
Follow Moberg Pharma AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
MOB015B, Vehicle (Placebo Comparator) - Onychomycosis | Phase 3 | Unknown | Moberg Pharma AB | 350 | 2022-05-09 | 2024-06-26 |
A Study of the Systemic Absorption of MOB015B
MOB015B - Onychomycosis | Phase 1 | Completed | Moberg Pharma AB | 20 | 2017-12-16 | 2018-05-03 |
Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design
MOB015B, 0.2% SLS, 0.9% Saline - Erythema | Phase 1 | Completed | Moberg Pharma AB | 45 | 2017-10-19 | 2024-04-17 |
Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design
MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline - Erythema | Phase 1 | Completed | Moberg Pharma AB | 250 | 2017-10-15 | 2024-04-17 |
A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
MOB015B, MOB015B Vehicle - Distal Subungual Onychomycosis | Phase 3 | Completed | Moberg Pharma AB | 365 | 2016-10-01 | 2020-12-24 |
Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
MOB015B, Ciclopirox 80 mg/g - Distal Subungual Onychomycosis | Phase 3 | Completed | Moberg Pharma AB | 452 | 2016-09-01 | 2020-10-06 |
An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
MOB015B - Distal Subungual Onychomycosis | Phase 2 | Completed | Moberg Pharma AB | | 2012-12-01 | 2014-09-22 |
Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis
MOB015 - Onychomycosis | Phase 2 | Completed | Moberg Pharma AB | 250 | 2010-12-01 | 2012-10-25 |
A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis
K101 nail solution - Onychomycosis | Not applicable | Completed | Moberg Pharma AB | 75 | 2010-09-01 | 2013-06-26 |
K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp
K301, Placebo - Seborrhoeic Eczema of the Scalp | Phase 3 | Completed | Moberg Pharma AB | 201 | 2008-02-01 | 2010-06-04 |
Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp
K40a, K40b, Placebo - Seborrhoeic Dermatitis of the Scalp | Phase 2 / Phase 3 | Completed | Moberg Pharma AB | 98 | 2007-02-01 | 2010-06-04 |
Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study
K201 - Atopic Dermatitis | Phase 1 / Phase 2 | Completed | Moberg Pharma AB | | | 2009-11-06 |
Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head
Imiquimod (topical use) - Actinic Keratosis | Phase 2 | Completed | Moberg Pharma AB | | | 2013-06-26 |
A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects
Imiquimod (topical use) - Healthy | Phase 1 | Completed | Moberg Pharma AB | | | 2012-05-28 |
Conditions studied
Onychomycosis (4) · Dermatitis, Seborrheic (2) · Erythema (2) · Dandruff (1) · Dermatitis, Atopic (1) · Keratosis, Actinic (1)
Interventions
Imiquimod (2) · Ciclopirox (1) · K201 compound (1) · Saline Solution (1) · Sodium Chloride (1) · long-chain-aldehyde dehydrogenase (1)
Countries
United States (5) · Germany (4) · Sweden (4) · Canada (2) · Poland (1) · United Kingdom (1)
Top investigators
Jan Faergemann, MD, PhD (1) · Jonathan S Dosik, MD (1) · Lennart Emtestam, MD (1)
Results publications
PMID 39158295